Chromadex Corp (NASDAQ: CDXC) on Monday, plunged -20.05% from the previous trading day, before settling in for the closing price of $3.69. Within the past 52 weeks, CDXC’s price has moved between $1.25 and $4.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.27%. The company achieved an average annual earnings per share of 78.57%. With a float of $44.68 million, this company’s outstanding shares have now reached $74.98 million.
Let’s determine the extent of company efficiency that accounts for 106 employees.
Chromadex Corp (CDXC) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Chromadex Corp is 40.67%, while institutional ownership is 15.49%. The most recent insider transaction that took place on Dec 01 ’23, was worth 7,050. In this transaction Chief Financial Officer of this company bought 5,000 shares at a rate of $1.41, taking the stock ownership to the 27,436 shares. Before that another transaction happened on Jun 12 ’23, when Company’s Director bought 7,000 for $1.69, making the entire transaction worth $11,830. This insider now owns 231,339 shares in total.
Chromadex Corp (CDXC) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 78.57% per share during the next fiscal year.
Chromadex Corp (NASDAQ: CDXC) Trading Performance Indicators
Chromadex Corp (CDXC) is currently performing well based on its current performance indicators. A quick ratio of 1.70 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.66. Likewise, its price to free cash flow for the trailing twelve months is 32.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.07, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach 0.06 in one year’s time.
Technical Analysis of Chromadex Corp (CDXC)
Looking closely at Chromadex Corp (NASDAQ: CDXC), its last 5-days average volume was 0.39 million, which is a jump from its year-to-date volume of 0.26 million. As of the previous 9 days, the stock’s Stochastic %D was 12.95%. Additionally, its Average True Range was 0.39.
During the past 100 days, Chromadex Corp’s (CDXC) raw stochastic average was set at 48.95%, which indicates a significant increase from 3.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 122.65% in the past 14 days, which was higher than the 83.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.70, while its 200-day Moving Average is $1.78. However, in the short run, Chromadex Corp’s stock first resistance to watch stands at $3.48. Second resistance stands at $4.02. The third major resistance level sits at $4.31. If the price goes on to break the first support level at $2.65, it is likely to go to the next support level at $2.36. Now, if the price goes above the second support level, the third support stands at $1.82.
Chromadex Corp (NASDAQ: CDXC) Key Stats
Market capitalization of the company is 222.16 million based on 75,309K outstanding shares. Right now, sales total 83,570 K and income totals -4,940 K. The company made 21,200 K in profit during its latest quarter, and 110 K in sales during its previous quarter.
